Perrigo Co. (Nasdaq: PRGO) Thursday announced that it is transferring the listing of its U.S. traded common stock to the New York Stock Exchange from the Nasdaq Global Select Market.
Perrigo Co. (Nasdaq: PRGO) Monday announced that it has closed the acquisition of Velcera Inc., the Yardley, Pa.-based pet health products company, for $160 million in cash.
Perrigo Co. (Nasdaq: PRGO) announced that it has filed with the U.S. Food and Drug Administration an Abbreviated New Drug Application for testosterone gel 1.62 percent and that it has notified AbbVie Inc., the owner of the Reference Listed Drug of its filing.
Perrigo Co., the Allegan-based over-the-counter health and beauty products and generic pharmaceutical maker, Monday announced a deal to acquire Leeds, England-based Rosemont Pharmaceuticals Ltd. for $283 million in cash.
Perrigo Company (Nasdaq: PRGO) announced that it has received U.S. Food and Drug Administration approval for its New Drug Application for testosterone gel 1%. Perrigo’s NDA included a bioequivalence study that compared its product to AbbVie’s AndroGel 1%.
The Allegan generic drugmaker Perrigo Co. Friday record revenue of $883 million for its second fiscal quarter ended Dec. 29, up from $838.2 million in the same quarter a year earlier. Net income for the quarter was $106 million or $1.12 a share, up from $99.7 million or $1.06 aa share in the same quarter a year earlier.
Perrigo Co. Friday announced that it has signed an agreement to acquire Yardley, Pa.-based Velcera Inc. for $160 million in cash.
Allegan’s Perrigo Co., the world’s largest makers of store brand infant formulas, Friday announced a new packaging look with new features.
Allegan-based Perrigo Co. (Nasdaq: PRGO) announced that it has agreed to settle its Hatch-Waxman litigation relating to Ofirmev (acetaminophen) injection brought by Cadence Pharmaceuticals Inc.
Perrigo Co. (Nasdaq: PRGO) Tuesday announced that its partner, Cobrek Pharmaceuticals Inc., received final approval from the United States Food and Drug Administration for its Abbreviated New Drug Application for betamethasone valerate foam 0.12 percent, the generic equivalent of Luxiq Foam.